Catalyst Pharmaceuticals (CPRX) FCF Margin (2018 - 2026)
Catalyst Pharmaceuticals posted quarterly FCF Margin of 39.87% for Q1 2026, down 259.0% year-on-year from 25.07% in Q1 2025, and up 35.64% on a QoQ basis from 29.39% in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 9 years of FCF Margin data on file, last reported at 39.87% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 259.0% year-over-year to 39.87%; the trailing twelve-month figure through Mar 2026 stood at 34.86% (down 1518.0% YoY), and the FY2025 full-year result was 35.42%, down 1324.0% from the prior year.
- FCF Margin for Q1 2026 stood at 39.87%, up from 29.39% in the prior quarter.
- Across five years, FCF Margin topped out at 72.15% in Q3 2022 and bottomed at 14.05% in Q1 2023.
- The 5-year median for FCF Margin is 43.88% (2023), against an average of 42.3%.
- The widest annual swing landed in 2024, when FCF Margin soared 2137 bps; it then plunged 3456 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 65.96% in 2022, then retreated by 24 bps to 50.25% in 2023, then slipped by 1 bps to 49.91% in 2024, then plunged by 41 bps to 29.39% in 2025, then jumped by 36 bps to 39.87% in 2026.
- The last three FCF Margin figures came in at 39.87% (Q1 2026), 29.39% (Q4 2025), and 21.86% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 39.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.87% |
| Dec 31, 2025 | 29.39% |
| Sep 30, 2025 | 21.86% |
| Jun 30, 2025 | 48.63% |
| Mar 31, 2025 | 42.46% |
| Dec 31, 2024 | 49.91% |
| Sep 30, 2024 | 56.42% |
| Jun 30, 2024 | 52.26% |
| Mar 31, 2024 | 32.21% |
| Dec 31, 2023 | 50.25% |
| Sep 30, 2023 | 43.88% |
| Jun 30, 2023 | 30.88% |
| Mar 31, 2023 | 14.05% |
| Dec 31, 2022 | 65.96% |
| Sep 30, 2022 | 72.15% |
| Jun 30, 2022 | 49.31% |
| Mar 31, 2022 | 19.68% |
| Dec 31, 2021 | 49.95% |
| Sep 30, 2021 | 60.19% |
| Jun 30, 2021 | 43.10% |
| Mar 31, 2021 | 9.61% |
| Dec 31, 2020 | 42.25% |
| Sep 30, 2020 | 39.06% |
| Jun 30, 2020 | 44.81% |
| Mar 31, 2020 | 24.76% |
| Dec 31, 2019 | 40.81% |
| Sep 30, 2019 | 52.63% |
| Jun 30, 2019 | 48.76% |
| Mar 31, 2019 | -64.44% |
| Dec 31, 2018 | -1,681.68% |